Titan Pharmaceuticals Inc (TTNP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) has a cash flow conversion efficiency ratio of -0.244x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-680.00K) by net assets ($2.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TTNP company net worth for the company's overall valuation and market capitalisation.
Titan Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Titan Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Titan Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore TTNP cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eo2 Société Anonyme
PA:ALEO2
|
-0.035x |
|
Pure Energy Minerals Ltd
V:PE
|
0.000x |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
0.042x |
|
Foresight Group Holdings Limited
LSE:FSG
|
0.305x |
|
Beowulf Mining PLC
ST:BEO-SDB
|
N/A |
|
SGF Capital Public Company Limited
BK:SGF
|
0.068x |
|
Norwest Minerals Ltd
AU:NWM
|
-0.015x |
|
Scandinavian Brake Systems A/S
CO:SBS
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Titan Pharmaceuticals Inc from 1995 to 2024. View Titan Pharmaceuticals Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.44 Million | $-3.88 Million | -1.590x | -48.93% |
| 2023-12-31 | $6.64 Million | $-7.09 Million | -1.068x | +82.22% |
| 2022-12-31 | $1.36 Million | $-8.18 Million | -6.004x | -290.52% |
| 2021-12-31 | $5.14 Million | $-7.90 Million | -1.537x | +68.44% |
| 2020-12-31 | $3.53 Million | $-17.20 Million | -4.871x | +54.81% |
| 2019-12-31 | $1.43 Million | $-15.45 Million | -10.778x | -773.27% |
| 2018-12-31 | $6.83 Million | $-8.43 Million | -1.234x | +91.89% |
| 2017-12-31 | $857.00K | $-13.04 Million | -15.214x | -3288.97% |
| 2016-12-31 | $13.19 Million | $6.29 Million | 0.477x | +144.67% |
| 2015-12-31 | $6.99 Million | $-7.47 Million | -1.068x | -56.82% |
| 2014-12-31 | $8.61 Million | $-5.87 Million | -0.681x | +59.96% |
| 2013-12-31 | $5.76 Million | $-9.80 Million | -1.701x | -2050.04% |
| 2012-12-31 | $-23.13 Million | $1.83 Million | -0.079x | -110.98% |
| 2011-12-31 | $-20.08 Million | $-14.48 Million | 0.721x | -6.29% |
| 2010-12-31 | $-6.05 Million | $-4.66 Million | 0.769x | -97.05% |
| 2009-12-31 | $-207.00K | $-5.41 Million | 26.121x | +285.55% |
| 2008-12-31 | $1.80 Million | $-25.34 Million | -14.078x | -2364.45% |
| 2007-12-31 | $26.59 Million | $-15.19 Million | -0.571x | +50.72% |
| 2006-12-31 | $11.65 Million | $-13.50 Million | -1.159x | +16.04% |
| 2005-12-31 | $16.60 Million | $-22.92 Million | -1.381x | -101.83% |
| 2004-12-31 | $34.95 Million | $-23.91 Million | -0.684x | -18.17% |
| 2003-12-31 | $45.67 Million | $-26.44 Million | -0.579x | -42.27% |
| 2002-12-31 | $71.98 Million | $-29.29 Million | -0.407x | -200.24% |
| 2001-12-31 | $101.37 Million | $-13.74 Million | -0.136x | -19.42% |
| 2000-12-31 | $115.98 Million | $-13.16 Million | -0.113x | +52.62% |
| 1999-12-31 | $45.50 Million | $-10.90 Million | -0.240x | +80.62% |
| 1998-12-31 | $10.60 Million | $-13.10 Million | -1.236x | -420.28% |
| 1997-12-31 | $18.40 Million | $7.10 Million | 0.386x | +145.02% |
| 1996-12-31 | $12.60 Million | $-10.80 Million | -0.857x | -145.85% |
| 1995-12-31 | $-4.60 Million | $-8.60 Million | 1.870x | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.